Search clinical trials for: ON 01910.Na

Total 3529 results

Onconova Therapeutics, Inc.

Completed

Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer

Neoplasms | Cancer | Advanced Cancer | Solid Tumors

United States
Onconova Therapeutics, Inc.

Completed

Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer

Neoplasms | Cancer | Advanced Cancer | Solid Tumors

United States
Onconova Therapeutics, Inc.

Completed

Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Onconova Therapeutics, Inc.

Completed

Oral Rigosertib for Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Anal Squamous Cell Carcinoma | Cervical Squamous Cell Carcinoma | Skin Squamous Cell Carcinoma | Lung Squamous Cell Carcinoma | Penile Squamous Cell Carcinoma

United States
Onconova Therapeutics, Inc.

Completed

Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Safety of ON 01910.Na in Patients With Myelodysplasia

Myelodysplastic Syndrome (MDS)

United States
Onconova Therapeutics, Inc.

Withdrawn

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Onconova Therapeutics, Inc.

Withdrawn

Three Dosing Schedules of Oral Rigosertib in MDS Patients

Myelodysplastic Syndrome

United States
Onconova Therapeutics, Inc.
The Leukemia and Lymphoma Society

Completed

Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts (ONTIME)

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | MDS | RAEB

United States, Belgium, Germany, Spain, France, Italy
M.D. Anderson Cancer Center
Onconova Therapeutics, Inc.

Terminated

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

Leukemia | Anemia | Myelofibrosis | Splenomegaly

United States
Onconova Therapeutics, Inc.

Completed

Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers

Healthy

United States
Onconova Therapeutics, Inc.

Completed

Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors

Solid Tumor

United States
Onconova Therapeutics, Inc.

Completed

Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients

Ovarian Cancer

United States
Onconova Therapeutics, Inc.

Completed

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

Myelodysplastic Syndromes

United States, France, Germany
Onconova Therapeutics, Inc.

Completed

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Cytopenia | Refractory Anemia With Excess Blasts

United States, Australia, Spain, Italy, Germany, France, Sweden, Denmark
Onconova Therapeutics, Inc.

Completed

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome (ONTARGET)

Myelodysplastic Syndrome | MDS | Trisomy 8

United States
Onconova Therapeutics, Inc.

Completed

Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer

Head and Neck Neoplasms | Carcinoma, Squamous Cell

United States
Onconova Therapeutics, Inc.

Completed

Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

United States, France
Onconova Therapeutics, Inc.

Completed

Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Chronic Lymphocytic Leukemia | Chronic Myelocytic Leukemia | Acute Lymphocytic Leukemia | Acute Myelocytic Leukemia

United States
Thomas Jefferson University
Onconova Therapeutics, Inc.

Recruiting

Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC

Recessive Dystrophic Epidermolysis Bullosa

United States
Onconova Therapeutics, Inc.

Terminated

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE)

Myelodysplastic Syndrome | MDS | Refractory Anemia With Excess Blasts | RAEB

United States, Spain, Canada, France, Australia, Switzerland, Israel, Japan, Belgium, India, Ireland, United Kingdom, Croatia, Czechia, Poland, Estonia, Germany, Italy, Austria, Hungary, Russian Federation, Sweden
National Heart, Lung, and Blood Institute (NHLBI)

Completed

A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies

Multiple Myeloma | Waldenstrom Macroglobulinemia | Leukemia, Lymphocytic, Chronic, B-Cell | Leukemia, Hairy Cell | Lymphoma, Mantle-cell

United States
Onconova Therapeutics, Inc.

Completed

Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk

Myelodysplastic Syndrome

United States
Onconova Therapeutics, Inc.

Completed

Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin

Advanced Solid Tumors

United States
Onconova Therapeutics, Inc.

Completed

Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma

Advanced Solid Tumor | Hepatoma

United States
Onconova Therapeutics, Inc.

Completed

Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors

Solid Tumors | Malignant Neoplasmas

United States
Onconova Therapeutics, Inc.
Academic GI Cancer Consortium (AGICC)

Completed

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer (ONTRAC)

Metastatic Pancreatic Adenocarcinoma

United States, India, Russian Federation, Hungary, Ukraine
Onconova Therapeutics, Inc.

Completed

Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors

Solid Tumor

United States
Onconova Therapeutics, Inc.

Completed

Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)

Chronic Myeloid Leukemia | Acute Lymphocytic Leukemia | Acute Myelocytic Leukemia | Myeloproliferative Disease

United States
STEBA France
STEBA LABORATORIES LTD.

Completed

Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers

Gastroesophageal Reflux | Esophagitis | Duodenal Ulcer | Stomach Ulcer

United States
University Health Network, Toronto

Unknown

Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues (Stop)

Chronic Hepatitis B

Canada
Prof. Johann Bauer

Recruiting

Rigosertib for RDEB-SCC

Epidermolysis Bullosa Dystrophica | Squamous Cell Carcinoma

Austria
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers

Healthy
Purdue University
Johns Hopkins University; University of California, San Diego; National Heart... and other collaborators

Terminated

DASH-Sodium Trial in Adolescents (CampDASH)

Blood High Pressure

United States
University College, London

Active, not recruiting

Exploiting Risk-Based Risk Stratification in Early Prostate Cancer to Discriminate Progressors From Non-Progressors (RECONCILE)

Prostate Cancer

United Kingdom
HaEmek Medical Center, Israel
Technion, Israel Institute of Technology

Unknown

Detection of Placenta Accreta Via Exhaled Women Breath

Placenta Accreta, Third Trimester

Israel
University of Manitoba

Unknown

Identifying a Sleep Screener for Disease Relapse in Children With Inflammatory Bowel Disease

IBD

Canada
STEBA France

Suspended

Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis

Esophagitis, Reflux

Canada
Icahn School of Medicine at Mount Sinai
Bristol-Myers Squibb; Onconova Therapeutics, Inc.

Recruiting

Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

Adenocarcinoma | Non-small Cell Lung Cancer | Stage IV

United States
PurGenesis Technologies Inc.

Completed

A Study to Assess the Safety and Tolerability of PUR 0110 Rectal Enema in Normal Healthy Volunteers

Ulcerative Colitis

Germany
NoNO Inc.
University of Calgary

Completed

Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke (ESCAPE-NA1)

Stroke, Acute

United States, Ireland, Korea, Republic of, Canada, Sweden, Germany, United Kingdom, Australia
Kresge Eye Institute

Suspended

Fluorescein Angiography With a Full-dose Versus a Half-dose of Intravenous Fluorescein

Fluorescein Angiography

United States
Boehringer Ingelheim

Completed

Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules

Hepatitis C

Japan
Changi General Hospital
National Taiwan University Hospital; Asan Medical Center

Completed

RCT: Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses

Pancreatic Diseases | Pancreatic Neoplasm

Singapore
University Hospital, Geneva
University of Geneva, Switzerland

Completed

Understanding COVID-19

SARS-CoV-2 Viral Kinetics and Host Immune Responses

Switzerland
King Khalid University

Unknown

Effect of Covid-19 Affliction on Psychological and Mental Health Among College Going Students: Cross-Sectional Survey

Covid19

Saudi Arabia
Children's Hospital of Philadelphia

Completed

Characterization of Cleft Lip and Palate Conditions in Guatemala

Cleft Lip and Palate | Cleft Palate | Cleft Lip

United States
The University of Hong Kong
Yan Chai Hospital

Completed

A Study on Effects of Acupressure Among the Frail Elderly in the Community Dwellings

Impaired

China
Austin Health

Completed

Endoscopy-related Phone Consultation During the COVID-19 Outbreak

Reflux, Gastroesophageal | Colon Disease | Colon Polyp | Varices, Esophageal

Australia
University Medical Center Groningen

Completed

The Identification of Phenotypes in Patients With Severe Chronic Obstructive Pulmonary Disease (Groningen Severe COPD Cohort)

Severe COPD

Search clinical trials for: ON 01910.Na

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations